source
- Sarepta Therapeutics appoints Michael Severino, former Tessera CEO, as new chief executiveSarepta Therapeutics announced that Michael Severino will become its chief executive, effective Tuesday. Severino previously led Tessera Therapeutics. He replaces Doug Ingram, who said he will ret…
- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.